Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (71-80 of 205) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Challenges in recognizing treatment-related neuroendocrine prostate cancerHimisha Beltran, Scott T Tagawa, Kyung Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline EndorsementMatthew I Milowsky, R Bryan Rumble, Christopher M Booth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumMatthew I Milowsky, David M Nanus, Fernando C Maluf, et al.
Cancer|October 14, 2009
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approachAndrew J Vickers, Angel M Cronin, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2018
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice GuidelineMichael J Morris, R Bryan Rumble, Ethan Basch, et al.
Case Reports in Oncological Medicine|September 25, 2024
A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate CancerAryan Dalal, Sean Clark-Garvey, Andrew Gdowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Microsystem Technologies : Sensors, Actuators, Systems Integration|October 29, 2014
Arrays of High-Aspect Ratio Microchannels for High-Throughput Isolation of Circulating Tumor Cells (CTCs)Mateusz L Hupert, Joshua M Jackson, Hong Wang, et al.
BJU International|November 27, 2013
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidityDavid C Johnson, Matthew E Nielsen, Jonathan Matthews, et al.
The Oncologist|April 19, 2015
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failureAngela K Green, Robert W Corty, William A Wood, et al.
Pageof 21

Showing results (71-80 of 205) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Challenges in recognizing treatment-related neuroendocrine prostate cancerHimisha Beltran, Scott T Tagawa, Kyung Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline EndorsementMatthew I Milowsky, R Bryan Rumble, Christopher M Booth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urotheliumMatthew I Milowsky, David M Nanus, Fernando C Maluf, et al.
Cancer|October 14, 2009
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approachAndrew J Vickers, Angel M Cronin, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2018
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice GuidelineMichael J Morris, R Bryan Rumble, Ethan Basch, et al.
Case Reports in Oncological Medicine|September 25, 2024
A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate CancerAryan Dalal, Sean Clark-Garvey, Andrew Gdowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumorsMatthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Microsystem Technologies : Sensors, Actuators, Systems Integration|October 29, 2014
Arrays of High-Aspect Ratio Microchannels for High-Throughput Isolation of Circulating Tumor Cells (CTCs)Mateusz L Hupert, Joshua M Jackson, Hong Wang, et al.
BJU International|November 27, 2013
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidityDavid C Johnson, Matthew E Nielsen, Jonathan Matthews, et al.
The Oncologist|April 19, 2015
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failureAngela K Green, Robert W Corty, William A Wood, et al.
Pageof 21